Gene Therapy for the Late Infantile Form of Batten Disease

Dolan Sondhi, Neil R. Hackett, Stephen M. Kaminsky, Mark M. Souweidane, Michael G. Kaplitt, Ronald Crystal

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter describes a program to assess gene transfer as a therapeutic approach to delay the neurological decline in children with the late infantile form of neuronal ceroid lipofuscinosis (LINCL). The disease arises from the autosomal-recessive inheritance of rare mutations in the CLN2 gene leading to a deficiency in the lysosomal protease tripeptidyl peptidase I (TPP-I). The challenge for a potential treatment is to obtain a therapeutic level of the target protein throughout the brain over the long term. Direct injection into the brain of a gene transfer vector derived from AAV serotype 2, AAV2cuhCLN2, was chosen as the most easily implemented approach to begin a human clinical study. The ongoing study provides an insight on the feasibility of this approach in slowing the neurodegeneration in children with LINCL as well as potentially using similar approaches to treat other neurodegenerative diseases of lysosomal storage.

Original languageEnglish
Title of host publicationGene Therapy of the Central Nervous System
Subtitle of host publicationFrom Bench to Bedside
PublisherElsevier Inc.
Pages317-333
Number of pages17
ISBN (Print)9780123976321
DOIs
Publication statusPublished - 1 Dec 2006
Externally publishedYes

Fingerprint

Ceroid
Neuronal Ceroid-Lipofuscinoses
Gene transfer
Gene therapy
Genetic Therapy
Brain
Neurodegenerative diseases
Direct injection
Genes
Peptide Hydrolases
Neurodegenerative Diseases
Therapeutics
Mutation
Injections
Proteins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Sondhi, D., Hackett, N. R., Kaminsky, S. M., Souweidane, M. M., Kaplitt, M. G., & Crystal, R. (2006). Gene Therapy for the Late Infantile Form of Batten Disease. In Gene Therapy of the Central Nervous System: From Bench to Bedside (pp. 317-333). Elsevier Inc.. https://doi.org/10.1016/B978-012397632-1/50025-3

Gene Therapy for the Late Infantile Form of Batten Disease. / Sondhi, Dolan; Hackett, Neil R.; Kaminsky, Stephen M.; Souweidane, Mark M.; Kaplitt, Michael G.; Crystal, Ronald.

Gene Therapy of the Central Nervous System: From Bench to Bedside. Elsevier Inc., 2006. p. 317-333.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sondhi, D, Hackett, NR, Kaminsky, SM, Souweidane, MM, Kaplitt, MG & Crystal, R 2006, Gene Therapy for the Late Infantile Form of Batten Disease. in Gene Therapy of the Central Nervous System: From Bench to Bedside. Elsevier Inc., pp. 317-333. https://doi.org/10.1016/B978-012397632-1/50025-3
Sondhi D, Hackett NR, Kaminsky SM, Souweidane MM, Kaplitt MG, Crystal R. Gene Therapy for the Late Infantile Form of Batten Disease. In Gene Therapy of the Central Nervous System: From Bench to Bedside. Elsevier Inc. 2006. p. 317-333 https://doi.org/10.1016/B978-012397632-1/50025-3
Sondhi, Dolan ; Hackett, Neil R. ; Kaminsky, Stephen M. ; Souweidane, Mark M. ; Kaplitt, Michael G. ; Crystal, Ronald. / Gene Therapy for the Late Infantile Form of Batten Disease. Gene Therapy of the Central Nervous System: From Bench to Bedside. Elsevier Inc., 2006. pp. 317-333
@inbook{5f663d3351ee4b3c8fba92bf8249930d,
title = "Gene Therapy for the Late Infantile Form of Batten Disease",
abstract = "This chapter describes a program to assess gene transfer as a therapeutic approach to delay the neurological decline in children with the late infantile form of neuronal ceroid lipofuscinosis (LINCL). The disease arises from the autosomal-recessive inheritance of rare mutations in the CLN2 gene leading to a deficiency in the lysosomal protease tripeptidyl peptidase I (TPP-I). The challenge for a potential treatment is to obtain a therapeutic level of the target protein throughout the brain over the long term. Direct injection into the brain of a gene transfer vector derived from AAV serotype 2, AAV2cuhCLN2, was chosen as the most easily implemented approach to begin a human clinical study. The ongoing study provides an insight on the feasibility of this approach in slowing the neurodegeneration in children with LINCL as well as potentially using similar approaches to treat other neurodegenerative diseases of lysosomal storage.",
author = "Dolan Sondhi and Hackett, {Neil R.} and Kaminsky, {Stephen M.} and Souweidane, {Mark M.} and Kaplitt, {Michael G.} and Ronald Crystal",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/B978-012397632-1/50025-3",
language = "English",
isbn = "9780123976321",
pages = "317--333",
booktitle = "Gene Therapy of the Central Nervous System",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Gene Therapy for the Late Infantile Form of Batten Disease

AU - Sondhi, Dolan

AU - Hackett, Neil R.

AU - Kaminsky, Stephen M.

AU - Souweidane, Mark M.

AU - Kaplitt, Michael G.

AU - Crystal, Ronald

PY - 2006/12/1

Y1 - 2006/12/1

N2 - This chapter describes a program to assess gene transfer as a therapeutic approach to delay the neurological decline in children with the late infantile form of neuronal ceroid lipofuscinosis (LINCL). The disease arises from the autosomal-recessive inheritance of rare mutations in the CLN2 gene leading to a deficiency in the lysosomal protease tripeptidyl peptidase I (TPP-I). The challenge for a potential treatment is to obtain a therapeutic level of the target protein throughout the brain over the long term. Direct injection into the brain of a gene transfer vector derived from AAV serotype 2, AAV2cuhCLN2, was chosen as the most easily implemented approach to begin a human clinical study. The ongoing study provides an insight on the feasibility of this approach in slowing the neurodegeneration in children with LINCL as well as potentially using similar approaches to treat other neurodegenerative diseases of lysosomal storage.

AB - This chapter describes a program to assess gene transfer as a therapeutic approach to delay the neurological decline in children with the late infantile form of neuronal ceroid lipofuscinosis (LINCL). The disease arises from the autosomal-recessive inheritance of rare mutations in the CLN2 gene leading to a deficiency in the lysosomal protease tripeptidyl peptidase I (TPP-I). The challenge for a potential treatment is to obtain a therapeutic level of the target protein throughout the brain over the long term. Direct injection into the brain of a gene transfer vector derived from AAV serotype 2, AAV2cuhCLN2, was chosen as the most easily implemented approach to begin a human clinical study. The ongoing study provides an insight on the feasibility of this approach in slowing the neurodegeneration in children with LINCL as well as potentially using similar approaches to treat other neurodegenerative diseases of lysosomal storage.

UR - http://www.scopus.com/inward/record.url?scp=84882837346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882837346&partnerID=8YFLogxK

U2 - 10.1016/B978-012397632-1/50025-3

DO - 10.1016/B978-012397632-1/50025-3

M3 - Chapter

AN - SCOPUS:84882837346

SN - 9780123976321

SP - 317

EP - 333

BT - Gene Therapy of the Central Nervous System

PB - Elsevier Inc.

ER -